# US 2024/0199561 A1 · Inhibitors of dyrk and pim

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199561 A1
- Document ID: US20240199561A1
- Status: Published application
- Kind: A1
- Application number: 18/261,563
- Filed: 2022-01-19
- Published: 2024-06-20
- Earliest claimed: 2021-01-19
- Assignees: Cold Spring Harbor Laboratory; Vichem Chemie Research, Ltd.; The Feinstein Institutes for Medical Research
- Applicants: Cold Spring Harbor Laboratory; The Feinstein Institutes for Medical Research; Vichem Chemie Research, Ltd.
- Inventors: Nicholas TONKS; Carla-Maria GAUSS; Prabhadevi VENKATARAMANI; Leemor JOSHUA-TOR; Elad ELKAYAM; Yousef Al ABED; Kai Fan CHENG; Ahmad ALTITI; Laszlo ORFI; Istvan SZABADKAI; Balint SZOKOL; Zoltan HORVATH
- Web page: https://patentgrep.com/patent/US20240199561A1

## CPC

- C07D 277/66: with aromatic rings or ring systems directly attached in position 2
- A61K 31/428: condensed with carbocyclic rings
- A61K 31/431: containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 513/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided is a compound, including a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein W is a direct bond or an optionally substituted C, and if W is a direct bond, then X1, X2, X3, and X4 are each independently H, OH, or an electrophile, and optionally one pair selected from X1 and X2, X2 and X3, and X3 and X4 forms a five-membered ring including one or more heteroatom, wherein the one or more heteroatom is selected from O, N, and S, and the five-membered ring is optionally substituted with a ═C, an ═S, or an electrophile, and Y1, Y2, Y3, Y4 and Y5 are each independently selected from H, CH3, OH, O—CH3, and NO2, and an electrophile, and optionally Y2 and Y3 form a five-membered ring including one or more heteroatom, wherein the one or more heteroatom is selected from O, N, and S, and the five-membered ring is optionally substituted with a ═C, ═S, or an electrophile.

## Claims

### Claim 1

A compound, comprising Formula I:
or a pharmaceutically acceptable salt thereof, wherein W is a direct bond or an optionally substituted C, and
if W is a direct bond, then X1, X2, X3, and X4 are each independently H, OH, or an electrophile, and optionally one pair selected from X1 and X2, X2 and X3, and X3 and X4 forms a five-membered ring including one or more heteroatom, wherein the one or more heteroatom is selected from O, N, and S, and the five-membered ring is optionally substituted with a ═C, an ═S, or an electrophile, and
Y1, Y2, Y3, Y4 and Y5 are each independently selected from H, CH3, OH, O—CH3, NO2, and an electrophile, and optionally Y2 and Y3 form a five-membered ring including one or more heteroatom, wherein the one or more heteroatom is selected from O, N, and S, and the five-membered ring is optionally substituted with a ═C, ═S, or an electrophile,
with the caveats that
(a) if the pair X2 and X3 together form a dioxolane then optionally Y2 and Y3 form a five-membered ring including one or more heteroatom only if Y2 and Y3 form a pyrroline optionally substituted with a ═C, ═S, or an electrophile, and no more than one of Y1, Y2, Y3, Y4 and Y5 is OH,
(b) if one or more of Y1, Y2, Y3, Y4 and Y5 is O—CH3, then X2 and X3 form a five-membered ring including one or more heteroatom, wherein the one or more heteroatom is selected from N and S, and the five-membered ring is optionally substituted with a ═C, ═S, or an electrophile,
(c) if X3 is OH and one or both of Y3 and Y4 are OH then Y5 is OH; and
(d) if W is an optionally substituted C, then
(i) at least one of X1, X2, X3, X4 is independently selected from OH, O—CH3, and a halogen, at least one of Y1, Y2, Y3, Y4, and Y5 is independently selected from OH, O—CH3, and a halogen, no more than five of X1, X2, X3, X4, Y1, Y2, Y3, Y4, and Y5 is H, and no more than one of X1, X2, X3, X4, Y1, Y2, Y3, Y4, and Y5, is O—CH3, or
(ii) X1, X4, Y1, Y4, and Y5 are hydrogen, X2 and X3 are OH or together form a dioxolane, and Y2 and Y3 are OH or together form a dioxolane.

### Claim 2 (depends on 1)

The compound of claim 1, wherein W is an optionally substituted C.

### Claim 3 (depends on 2)

The compound of claim 2, wherein W comprises —C(═O)—.

### Claim 4 (depends on 2, 3)

The compound of claim 2 or 3, wherein at least one of X1, X2, X3, X4 is independently selected from OH, O—CH3, and a halogen, at least one of Y1, Y2, Y3, Y4, and Y5 is independently selected from OH, O—CH3, and a halogen, no more than five of X1, X2, X3, X4, Y1, Y2, Y3, Y4, and Y5 is H, and no more than one of X1, X2, X3, X4, Y1, Y2, Y3, Y4, and Y5, is O—CH3.

### Claim 5 (depends on 2, 3)

The compound of claim 2 or 3, wherein X1, X4, Y1, Y4, and Y5 are hydrogen, X2 and X3 are OH or together form a dioxolane, and Y2 and Y3 are OH or together form a dioxolane.

### Claim 6 (depends on 1)

The compound of claim 1, wherein the compound is selected from

### Claim 7 (depends on 1)

The compound of claim 1, comprising Formula Ia:
or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 7)

The compound of claim 7, wherein X1 and X2, or X3 and X4, form an imidazole or a triazole.

### Claim 9 (depends on 7)

The compound of claim 7, wherein X2 and X3 form a five-membered ring selected from a pyrrole, a dioxolane, a pyrazole, an imidazole, and a triazole.

### Claim 10 (depends on 7)

The compound of claim 7, wherein X2 and X3 form a five-membered ring comprising a substitution, the five-membered ring is selected from a pyrroline and a tetrahydrofuran, and the substitution is selected from ═O, ═S, and an electrophile.

### Claim 11 (depends on 7)

The compound of claim 7, wherein X2 and X3 form a thiazole comprising a substitution, and the substitution is selected from ═O, ═S, and an electrophile.

### Claim 12 (depends on 7)

The compound of claim 7, wherein X2 and X3 form a dioxolane.

### Claim 13 (depends on 12)

The compound of claim 12, wherein Y2 and Y3 form a five-membered ring.

### Claim 14 (depends on 13)

The compound of claim 13, wherein Y2 and Y3 form a furan, a pyrrole, or a thiophene.

### Claim 15 (depends on 7)

The compound of claim 7, wherein Y2 and Y3 form a five-membered ring comprising a substitution, wherein the five-membered ring is selected from a pyrroline and a thiazole, and the substitution is selected from ═O, ═S, and an electrophile.

### Claim 16 (depends on 7)

The compound of claim 7, wherein the compound is selected from

### Claim 17 (depends on 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The compound of any one of claims 1 through 5 and 7 through 15, wherein the electrophile is selected from
wherein R═H or any alkyl or any carbonyl, and X=any halogen, ether, amine, thiol, or thioether.

### Claim 18 (depends on 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The compound of any one of claims 1 through 5 and 7 through 15, wherein the compound is not substituted with an electrophile.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A pharmaceutical composition, comprising the compound of any one of claims 1 through 18 and a pharmaceutically acceptable excipient.

### Claim 20 (depends on 19)

A method, comprising administering a pharmaceutical composition of claim 19 to a subject, wherein the subject is diagnosed with or at risk of developing cancer.

### Claim 21 (depends on 20)

The method of claim 20, further comprising administering an epidermal growth factor receptor (EGFR) inhibitor in combination with the pharmaceutical composition, or wherein the pharmaceutical composition further comprises the EGFR inhibitor.

### Claim 22 (depends on 21)

The method of claim 21, wherein the EGFR inhibitor comprises AZD9291.

### Claim 23 (depends on 20, 21, 22)

The method of any one of claims 20 through 22, wherein the cancer is selected from acute megakaryoplastic leukemia, glioblastoma, and non-small cell lung cancer.

### Claim 24 (depends on 19)

A method, comprising treating an impairment in a subject, wherein the impairment includes a cognitive impairment or an affective impairment, and the treating comprises administering the pharmaceutical composition of claim 19 to the subject.

### Claim 25 (depends on 26)

The method of claim 26, wherein the subject is diagnosed with Down syndrome.

### Claim 26 (depends on 26)

The method of claim 26, wherein the subject is diagnosed with or at risk for developing Alzheimer's disease.

### Claim 27 (depends on 19)

A method, comprising administering the pharmaceutical composition of claim 19 to a subject, wherein the subject is diagnosed with or at risk for developing Alzheimer's disease.

### Claim 28 (depends on 19)

A method, comprising administering a pharmaceutical composition of claim 19 to a subject, wherein the subject is diagnosed with Down syndrome.

### Claim 29

A compound, comprising Formula I:
or a pharmaceutically acceptable salt thereof, wherein
W is an optionally substituted C,
at least one of X1, X2, X3, X4 is independently selected from OH, O—CH3, and a halogen,
Y1, Y2, Y3, Y4 and Y5 are each independently selected from H, CH3, OH, O—CH3, NO2, and an electrophile, at least one of Y1, Y2, Y3, Y4, and Y5 is independently selected from OH and O—CH3, and a halogen, and optionally Y2 and Y3 form a five-membered ring including one or more heteroatom, wherein the one or more heteroatom is selected from O, N, and S, and the five-membered ring is optionally substituted with a ═C, ═S, or an electrophile, and
no more than five of X1, X2, X3, X4, Y1, Y2, Y3, Y4, and Y5 is H, and no more than one of X1, X2, X3, X4, Y1, Y2, Y3, Y4, and Y5, is O—CH3.

### Claim 30 (depends on 29)

The compound of claim 29, wherein W comprises —C(═O)—.

### Claim 31 (depends on 29, 30)

The compound of claim 29 or 30, wherein the compound is selected from

### Claim 32 (depends on 29, 30, 31)

The compound of any one of claims 29 through 31, wherein the electrophile is selected from
wherein R═H or any alkyl or any carbonyl, and X=any halogen, ether, amine, thiol, or thioether.

### Claim 33 (depends on 29, 30, 31)

The compound of any one of claims 29 through 31, wherein the compound is not substituted with an electrophile.

### Claim 34 (depends on 29, 30, 31, 32, 33)

A pharmaceutical composition, comprising the compound of any one of claims 29 through 33 and a pharmaceutically acceptable excipient.

### Claim 35

A compound, comprising Formula I:
or a pharmaceutically acceptable salt thereof, wherein
W is an optionally substituted C, and
X1, X4, Y1, Y4, and Y5 are hydrogen, X2 and X3 are OH or together form a dioxolane, and Y2 and Y3 are OH or together form a dioxolane.

### Claim 36 (depends on 35)

The compound of claim 35, wherein W comprises —C(═O)—.

### Claim 37 (depends on 35, 36)

The compound of claim 35 or 36, wherein the compound is

### Claim 38 (depends on 35, 36, 37)

A pharmaceutical composition, comprising the compound of any one of claims 35 through 37 and a pharmaceutically acceptable excipient.

### Claim 39

A compound, comprising Formula Ia:
or a pharmaceutically acceptable salt thereof, wherein
X1, X2, X3, and X4 are each independently H, OH, or an electrophile, and optionally one pair selected from X1 and X2, X2 and X3, and X3 and X4 forms a five-membered ring including one or more heteroatom, wherein the one or more heteroatom is selected from O, N, and S, and the five-membered ring is optionally substituted with a ═C, an ═S, or an electrophile, and
Y1, Y2, Y3, Y4 and Y5 are each independently selected from H, CH3, OH, O—CH3, NO2, and an electrophile, and optionally Y2 and Y3 form a five-membered ring including one or more heteroatom, wherein the one or more heteroatom is selected from O, N, and S, and the five-membered ring is optionally substituted with a ═C, ═S, or an electrophile,
with the caveats that
(a) if the pair X2 and X3 together form a dioxolane then optionally Y2 and Y3 form a pyrroline optionally substituted with a ═C, ═S, or an electrophile, and no more than one of Y1, Y2, Y3, Y4 and Y5 is OH,
(b) if one or more of Y1, Y2, Y3, Y4 and Y5 is O—CH3, then X2 and X3 form a five-membered ring including one or more heteroatom, wherein the one or more heteroatom is selected from N and S, and the five-membered ring is optionally substituted with a ═C, ═S, or an electrophile, and
(c) if X3 is OH and one or both of Y3 and Y4 are OH then Y5 is OH.

### Claim 40 (depends on 39)

The compound of claim 39, wherein X1 and X2, or X3 and X4, form an imidazole or a triazole.

### Claim 41 (depends on 39)

The compound of claim 39, wherein X2 and X3 form a five-membered ring selected from a pyrrole, a dioxolane, a pyrazole, an imidazole, and a triazole.

### Claim 42 (depends on 39)

The compound of claim 39, wherein X2 and X3 form a five-membered ring comprising a substitution, the five-membered ring is selected from a pyrroline and a tetrahydrofuran, and the substitution is selected from ═O, ═S, and an electrophile.

### Claim 43 (depends on 40)

The compound of claim 40, wherein X2 and X3 form a thiazole comprising a substitution, and the substitution is selected from ═O, ═S, and an electrophile.

### Claim 44 (depends on 39)

The compound of claim 39, wherein X2 and X3 form a dioxolane.

### Claim 45 (depends on 44)

The compound of claim 44, wherein Y2 and Y3 form a five-membered ring.

### Claim 46 (depends on 45)

The compound of claim 45, wherein Y2 and Y3 form a furan, a pyrrole, or a thiophene.

### Claim 47 (depends on 39)

The compound of claim 39, wherein Y2 and Y3 form a five-membered ring comprising a substitution, wherein the five-membered ring is selected from a pyrroline and a thiazole, and the substitution is selected from ═O, ═S, and an electrophile.

### Claim 48 (depends on 39)

The compound of claim 39, wherein the compound is selected from

### Claim 49 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The compound of any one of claims 39 through 48, wherein the electrophile is selected from
wherein R═H or any alkyl or any carbonyl, and X=any halogen, ether, amine, thiol, or thioether.

### Claim 50 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The compound of any one of claims 39 through 48, wherein the compound is not substituted with an electrophile.

### Claim 51 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

A pharmaceutical composition, comprising the compound of any one of claims 39 through 50 and a pharmaceutically acceptable excipient.

### Claim 52

A compound, comprising Formula Ia:
or a pharmaceutically acceptable salt thereof, wherein
X1, X2, X3, and X4 are each independently H, OH, or an electrophile, and optionally one pair selected from X1 and X2, X2 and X3, and X3 and X4 forms a five-membered ring including one or more heteroatom, wherein the one or more heteroatom is selected from O, N, and S, and the five-membered ring is not a dioxolane and is optionally substituted with a ═C, an ═S, or an electrophile, and
Y1, Y2, Y3, Y4 and Y5 are each independently selected from H, CH3, OH, O—CH3, NO2, and an electrophile, and optionally Y2 and Y3 form a five-membered ring including one or more heteroatom, wherein the one or more heteroatom is selected from O, N, and S, and the five-membered ring is optionally substituted with a ═C, ═S, or an electrophile,
with the caveats that
(a) if one or more of Y1, Y2, Y3, Y4 and Y5 is O—CH3, then X2 and X3 form a five-membered ring including one or more heteroatom, wherein the one or more heteroatom is selected from N and S, and the five-membered ring is optionally substituted with a ═C, ═S, or an electrophile, and
(b) if X3 is OH and one or both of Y3 and Y4 are OH then Y5 is OH.

### Claim 53 (depends on 52)

The compound of claim 52, wherein X1 and X2, or X3 and X4, form an imidazole or a triazole.

### Claim 54 (depends on 52)

The compound of claim 52, wherein X2 and X3 form a five-membered ring selected from a pyrrole, a dioxolane, a pyrazole, an imidazole, and a triazole.

### Claim 55 (depends on 52)

The compound of claim 52, wherein X2 and X3 form a five-membered ring comprising a substitution, the five-membered ring is selected from a pyrroline and a tetrahydrofuran, and the substitution is selected from ═O, ═S, and an electrophile.

### Claim 56 (depends on 52)

The compound of claim 52, wherein X2 and X3 form a thiazole comprising a substitution, and the substitution is selected from ═O, ═S, and an electrophile.

### Claim 57 (depends on 52)

The compound of claim 52, wherein X2 and X3 form a dioxolane.

### Claim 58 (depends on 57)

The compound of claim 57, wherein Y2 and Y3 form a five-membered ring.

### Claim 59 (depends on 58)

The compound of claim 58, wherein Y2 and Y3 form a furan, a pyrrole, or a thiophene.

### Claim 60 (depends on 52)

The compound of claim 52, wherein Y2 and Y3 form a five-membered ring comprising a substitution, wherein the five-membered ring is selected from a pyrroline and a thiazole, and the substitution is selected from ═O, ═S, and an electrophile.

### Claim 61 (depends on 52)

The compound of claim 52, wherein the compound is selected from

### Claim 62 (depends on 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The compound of any one of claims 52 through 61, wherein the electrophile is selected from
wherein R═H or any alkyl or any carbonyl, and X=any halogen, ether, amine, thiol, or thioether.

### Claim 63 (depends on 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The compound of any one of claims 52 through 61, wherein the compound is not substituted with an electrophile.

### Claim 64 (depends on 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

A pharmaceutical composition, comprising the compound of any one of claims 52 through 63 and a pharmaceutically acceptable excipient.

### Claim 65

A compound, comprising Formula Ia:
or a pharmaceutically acceptable salt thereof, wherein
X1, X2, X3, and X4 are each independently H, OH, or an electrophile, and optionally one pair selected from X1 and X2, X2 and X3, and X3 and X4 forms a five-membered ring including one or more heteroatom, wherein the one or more heteroatom is selected from O, N, and S, and the five-membered ring is optionally substituted with a ═C, an ═S, or an electrophile, and
Y1, Y2, Y3, Y4 and Y5 are each independently selected from H, CH3, OH, NO2, and an electrophile, and optionally Y2 and Y3 form a five-membered ring including one or more heteroatom, wherein the one or more heteroatom is selected from O, N, and S, and the five-membered ring is optionally substituted with a ═C, ═S, or an electrophile,
with the caveats that
(a) if the pair X2 and X3 together form a dioxolane then optionally Y2 and Y3 form a five-membered ring including one or more heteroatom only if Y2 and Y3 form a pyrroline optionally substituted with a ═C, ═S, or an electrophile, and no more than one of Y1, Y2, Y3, Y4 and Y5 is OH, and.
(b) if X3 is OH and one or both of Y3 and Y4 are OH then Y5 is OH

### Claim 66 (depends on 65)

The compound of claim 65, wherein X1 and X2, or X3 and X4, form an imidazole or a triazole.

### Claim 67 (depends on 65)

The compound of claim 65, wherein X2 and X3 form a five-membered ring selected from a pyrrole, a dioxolane, a pyrazole, an imidazole, and a triazole.

### Claim 68 (depends on 65)

The compound of claim 65, wherein X2 and X3 form a five-membered ring comprising a substitution, the five-membered ring is selected from a pyrroline and a tetrahydrofuran, and the substitution is selected from ═O, ═S, and an electrophile.

### Claim 69 (depends on 65)

The compound of claim 65, wherein X2 and X3 form a thiazole comprising a substitution, and the substitution is selected from ═O, ═S, and an electrophile.

### Claim 70 (depends on 65)

The compound of claim 65, wherein X2 and X3 form a dioxolane.

### Claim 71 (depends on 70)

The compound of claim 70, wherein Y2 and Y3 form a five-membered ring.

### Claim 72 (depends on 71)

The compound of claim 71, wherein Y2 and Y3 form a furan, a pyrrole, or a thiophene.

### Claim 73 (depends on 65)

The compound of claim 65, wherein Y2 and Y3 form a five-membered ring comprising a substitution, wherein the five-membered ring is selected from a pyrroline and a thiazole, and the substitution is selected from ═O, ═S, and an electrophile.

### Claim 74 (depends on 65)

The compound of claim 65, wherein the compound is selected from

### Claim 75 (depends on 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The compound of any one of claims 65 through 74, wherein the electrophile is selected from
wherein R═H or any alkyl or any carbonyl, and X=any halogen, ether, amine, thiol, or thioether.

### Claim 76 (depends on 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The compound of any one of claims 65 through 74, wherein the compound is not substituted with an electrophile.

### Claim 77 (depends on 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

A pharmaceutical composition, comprising the compound of any one of claims 65 through 76 and a pharmaceutically acceptable excipient.

### Claim 78 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

A method, comprising administering the compound or pharmaceutical acceptable salt thereof of any one of claims 29 through 33, 35 through 37, 39 through 50, 52 through 63, 65 through 76, or pharmaceutical composition of any one of claim 34, 38, 51, 64, or 77 to a subject, wherein the subject is diagnosed with or at risk of developing cancer.

### Claim 79 (depends on 78)

The method of claim 78, further comprising administering an epidermal growth factor receptor (EGFR) inhibitor in combination with the pharmaceutical composition, or wherein the pharmaceutical composition further comprises the EGFR inhibitor.

### Claim 80 (depends on 79)

The method of claim 79, wherein the EGFR inhibitor comprises AZD9291.

### Claim 81 (depends on 78, 79, 80)

The method of any one of claims 78 through 80, wherein the cancer is selected from acute megakaryoplastic leukemia, glioblastoma, and non-small cell lung cancer.

### Claim 82 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

A method, comprising treating an impairment in a subject, wherein the impairment includes a cognitive impairment or an affective impairment, and the treating comprises administering the compound or pharmaceutical acceptable salt thereof of any one of claims 29 through 33, 35 through 37, 39 through 50, 52 through 63, 65 through 76, or pharmaceutical composition of any one of claim 34, 38, 51, 64, or 77 to the subject.

### Claim 83 (depends on 82)

The method of claim 82, wherein the subject is diagnosed with Down syndrome.

### Claim 84 (depends on 82)

The method of claim 82, wherein the subject is diagnosed with or at risk for developing Alzheimer's disease.

### Claim 85 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

A method, comprising administering the compound or pharmaceutical acceptable salt thereof of any one of claims 29 through 33, 35 through 37, 39 through 50, 52 through 63, 65 through 76, or pharmaceutical composition of any one of claim 34, 38, 51, 64, or 77 to a subject, wherein the subject is diagnosed with or at risk for developing Alzheimer's disease.

### Claim 86 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

A method, comprising administering the compound or pharmaceutical acceptable salt thereof of any one of claims 29 through 33, 35 through 37, 39 through 50, 52 through 63, 65 through 76, or pharmaceutical composition of any one of claim 34, 38, 51, 64, or 77 to a subject, wherein the subject is diagnosed with Down syndrome.
